Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pregnancy Complications | 47 | 2024 | 2942 | 6.380 |
Why?
|
Depression, Postpartum | 30 | 2023 | 345 | 6.170 |
Why?
|
Depressive Disorder, Major | 51 | 2022 | 4744 | 4.610 |
Why?
|
Antidepressive Agents | 40 | 2023 | 2890 | 3.720 |
Why?
|
Antipsychotic Agents | 30 | 2024 | 3061 | 3.330 |
Why?
|
Psychiatry | 21 | 2021 | 1689 | 3.250 |
Why?
|
Fatty Acids, Omega-3 | 27 | 2022 | 1387 | 2.900 |
Why?
|
Women's Health | 17 | 2024 | 2056 | 2.620 |
Why?
|
Abnormalities, Drug-Induced | 10 | 2023 | 338 | 2.490 |
Why?
|
Puerperal Disorders | 8 | 2024 | 300 | 2.480 |
Why?
|
Mental Disorders | 31 | 2024 | 6796 | 2.430 |
Why?
|
Pregnancy | 94 | 2024 | 29749 | 2.190 |
Why?
|
Complementary Therapies | 9 | 2013 | 486 | 2.150 |
Why?
|
Depressive Disorder | 17 | 2023 | 3726 | 1.550 |
Why?
|
Ketamine | 8 | 2022 | 516 | 1.490 |
Why?
|
Periodicals as Topic | 7 | 2024 | 1469 | 1.440 |
Why?
|
Perinatal Care | 6 | 2019 | 242 | 1.380 |
Why?
|
Mood Disorders | 6 | 2023 | 1124 | 1.350 |
Why?
|
Mental Health | 9 | 2024 | 3213 | 1.280 |
Why?
|
Depression | 23 | 2023 | 8044 | 1.240 |
Why?
|
Menopause | 9 | 2017 | 1640 | 1.240 |
Why?
|
Reproduction | 4 | 2022 | 646 | 1.200 |
Why?
|
Bipolar Disorder | 17 | 2022 | 5078 | 1.110 |
Why?
|
Valproic Acid | 6 | 2022 | 441 | 1.090 |
Why?
|
Urea | 5 | 2020 | 446 | 1.080 |
Why?
|
Registries | 19 | 2024 | 8469 | 1.020 |
Why?
|
Postpartum Period | 11 | 2024 | 1167 | 1.010 |
Why?
|
Eicosapentaenoic Acid | 7 | 2019 | 613 | 0.990 |
Why?
|
Career Mobility | 4 | 2012 | 258 | 0.950 |
Why?
|
Pregnancy Outcome | 7 | 2022 | 2907 | 0.940 |
Why?
|
Female | 150 | 2024 | 391270 | 0.910 |
Why?
|
Publishing | 3 | 2024 | 836 | 0.910 |
Why?
|
Psychotropic Drugs | 3 | 2018 | 883 | 0.870 |
Why?
|
Scientific Misconduct | 1 | 2024 | 74 | 0.860 |
Why?
|
Hot Flashes | 7 | 2020 | 328 | 0.860 |
Why?
|
Docosahexaenoic Acids | 7 | 2019 | 912 | 0.860 |
Why?
|
Psychotic Disorders | 6 | 2024 | 3193 | 0.830 |
Why?
|
Antimanic Agents | 5 | 2016 | 520 | 0.820 |
Why?
|
Psychiatric Status Rating Scales | 19 | 2021 | 6015 | 0.820 |
Why?
|
Central Nervous System Stimulants | 4 | 2023 | 1174 | 0.810 |
Why?
|
Humans | 198 | 2024 | 760621 | 0.800 |
Why?
|
Dietary Supplements | 9 | 2022 | 3392 | 0.760 |
Why?
|
Psychotherapy | 7 | 2020 | 1640 | 0.760 |
Why?
|
Infant, Newborn, Diseases | 3 | 2018 | 592 | 0.750 |
Why?
|
Peer Review | 2 | 2014 | 218 | 0.740 |
Why?
|
Anxiety Disorders | 5 | 2018 | 2714 | 0.730 |
Why?
|
Perimenopause | 4 | 2020 | 141 | 0.720 |
Why?
|
Piperidines | 6 | 2020 | 1650 | 0.710 |
Why?
|
Infertility, Female | 2 | 2018 | 759 | 0.700 |
Why?
|
Anticonvulsants | 6 | 2022 | 1879 | 0.690 |
Why?
|
Citalopram | 2 | 2017 | 402 | 0.670 |
Why?
|
Tetrahydrofolates | 1 | 2019 | 58 | 0.630 |
Why?
|
Methylphenidate | 2 | 2023 | 488 | 0.620 |
Why?
|
S-Adenosylmethionine | 5 | 2013 | 213 | 0.620 |
Why?
|
Deception | 1 | 2019 | 98 | 0.610 |
Why?
|
Clinical Trials as Topic | 11 | 2017 | 8056 | 0.600 |
Why?
|
Adult | 78 | 2024 | 219994 | 0.600 |
Why?
|
Fish Oils | 3 | 2011 | 482 | 0.590 |
Why?
|
Sertraline | 2 | 2009 | 208 | 0.580 |
Why?
|
Norepinephrine | 1 | 2020 | 900 | 0.580 |
Why?
|
Benzodiazepines | 4 | 2022 | 1131 | 0.570 |
Why?
|
Anxiety | 9 | 2023 | 4538 | 0.570 |
Why?
|
Sulfides | 1 | 2017 | 171 | 0.560 |
Why?
|
Estrogens | 3 | 2013 | 1520 | 0.550 |
Why?
|
Interview, Psychological | 2 | 2017 | 810 | 0.540 |
Why?
|
Piperazines | 3 | 2017 | 2525 | 0.530 |
Why?
|
Peer Review, Research | 2 | 2009 | 340 | 0.520 |
Why?
|
Psychotherapy, Brief | 2 | 2014 | 118 | 0.520 |
Why?
|
Pregnancy Trimester, First | 7 | 2023 | 908 | 0.520 |
Why?
|
Drug Labeling | 1 | 2018 | 251 | 0.520 |
Why?
|
Double-Blind Method | 23 | 2023 | 12427 | 0.510 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 4 | 2023 | 3701 | 0.510 |
Why?
|
Serotonin | 2 | 2020 | 1040 | 0.510 |
Why?
|
Research | 5 | 2018 | 1974 | 0.500 |
Why?
|
Prenatal Care | 3 | 2019 | 1129 | 0.500 |
Why?
|
Treatment Outcome | 42 | 2023 | 65017 | 0.480 |
Why?
|
Stress, Psychological | 4 | 2021 | 4446 | 0.480 |
Why?
|
Hostility | 1 | 2015 | 183 | 0.480 |
Why?
|
Mothers | 6 | 2024 | 2186 | 0.480 |
Why?
|
Paroxetine | 3 | 2012 | 182 | 0.480 |
Why?
|
Antidepressive Agents, Second-Generation | 2 | 2009 | 489 | 0.480 |
Why?
|
Premenopause | 1 | 2019 | 1038 | 0.470 |
Why?
|
Breast Feeding | 5 | 2021 | 1355 | 0.470 |
Why?
|
Cyclopropanes | 1 | 2016 | 431 | 0.470 |
Why?
|
Lithium | 4 | 2005 | 596 | 0.460 |
Why?
|
Object Attachment | 2 | 2014 | 324 | 0.450 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2018 | 497 | 0.450 |
Why?
|
Postmenopause | 3 | 2020 | 2509 | 0.450 |
Why?
|
Family Planning Services | 1 | 2016 | 265 | 0.430 |
Why?
|
Anger | 1 | 2015 | 401 | 0.430 |
Why?
|
Placebo Effect | 1 | 2017 | 520 | 0.420 |
Why?
|
Mass Screening | 7 | 2023 | 5423 | 0.420 |
Why?
|
Phytotherapy | 3 | 2010 | 295 | 0.420 |
Why?
|
Hypericum | 5 | 2013 | 58 | 0.420 |
Why?
|
Mother-Child Relations | 2 | 2014 | 491 | 0.410 |
Why?
|
Time Management | 1 | 2012 | 52 | 0.410 |
Why?
|
Contraception | 1 | 2016 | 349 | 0.410 |
Why?
|
Phototherapy | 6 | 2013 | 368 | 0.410 |
Why?
|
Drug Monitoring | 3 | 2015 | 965 | 0.410 |
Why?
|
Peripartum Period | 1 | 2013 | 138 | 0.400 |
Why?
|
Child Rearing | 1 | 2012 | 73 | 0.400 |
Why?
|
Fatigue | 2 | 2016 | 1544 | 0.390 |
Why?
|
Aminopyridines | 1 | 2015 | 564 | 0.390 |
Why?
|
Hypertriglyceridemia | 1 | 2015 | 316 | 0.390 |
Why?
|
Patient Selection | 5 | 2017 | 4283 | 0.390 |
Why?
|
Women, Working | 1 | 2012 | 86 | 0.390 |
Why?
|
Secondary Prevention | 4 | 2020 | 1548 | 0.380 |
Why?
|
Capsules | 1 | 2011 | 192 | 0.380 |
Why?
|
Pre-Eclampsia | 2 | 2018 | 1229 | 0.380 |
Why?
|
Patient Acceptance of Health Care | 3 | 2024 | 3164 | 0.380 |
Why?
|
Hospitals, General | 6 | 2023 | 795 | 0.370 |
Why?
|
Community Mental Health Services | 1 | 2014 | 392 | 0.370 |
Why?
|
Altruism | 1 | 2013 | 205 | 0.370 |
Why?
|
Taste | 1 | 2011 | 188 | 0.350 |
Why?
|
Dysthymic Disorder | 1 | 2010 | 75 | 0.350 |
Why?
|
Women | 1 | 2011 | 225 | 0.340 |
Why?
|
Biomedical Research | 4 | 2021 | 3426 | 0.340 |
Why?
|
Sex Characteristics | 2 | 2019 | 2629 | 0.340 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 1677 | 0.340 |
Why?
|
Mentors | 3 | 2012 | 661 | 0.340 |
Why?
|
Cesarean Section | 1 | 2018 | 1385 | 0.330 |
Why?
|
Young Adult | 24 | 2024 | 58741 | 0.330 |
Why?
|
Middle Aged | 44 | 2022 | 220352 | 0.320 |
Why?
|
Nortriptyline | 1 | 2009 | 79 | 0.320 |
Why?
|
Gestational Age | 3 | 2016 | 3565 | 0.320 |
Why?
|
Motivation | 1 | 2019 | 1993 | 0.320 |
Why?
|
Thiophenes | 1 | 2013 | 587 | 0.310 |
Why?
|
Massachusetts | 10 | 2024 | 8803 | 0.310 |
Why?
|
Lithium Compounds | 2 | 2009 | 225 | 0.310 |
Why?
|
Hypercholesterolemia | 1 | 2015 | 1155 | 0.310 |
Why?
|
Acupuncture Therapy | 5 | 2013 | 480 | 0.310 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2020 | 10827 | 0.300 |
Why?
|
Perinatology | 1 | 2008 | 62 | 0.300 |
Why?
|
Premature Birth | 2 | 2023 | 1771 | 0.290 |
Why?
|
Dibenzothiazepines | 2 | 2007 | 102 | 0.290 |
Why?
|
Child, Hospitalized | 1 | 2009 | 182 | 0.290 |
Why?
|
Carbamazepine | 4 | 2014 | 224 | 0.280 |
Why?
|
Prospective Studies | 17 | 2023 | 54303 | 0.280 |
Why?
|
Electronic Mail | 1 | 2009 | 213 | 0.280 |
Why?
|
Vitamins | 1 | 2015 | 1634 | 0.280 |
Why?
|
Drug Therapy, Combination | 12 | 2022 | 6498 | 0.280 |
Why?
|
Pregnant Women | 3 | 2023 | 563 | 0.280 |
Why?
|
Risperidone | 3 | 2007 | 379 | 0.280 |
Why?
|
Prenatal Exposure Delayed Effects | 4 | 2024 | 2496 | 0.280 |
Why?
|
Reproductive Medicine | 1 | 2008 | 100 | 0.280 |
Why?
|
Review Literature as Topic | 1 | 2009 | 349 | 0.280 |
Why?
|
Gender Identity | 1 | 2012 | 698 | 0.280 |
Why?
|
Nutrition Assessment | 1 | 2010 | 727 | 0.270 |
Why?
|
Combined Modality Therapy | 7 | 2018 | 8552 | 0.270 |
Why?
|
Physicians, Women | 1 | 2012 | 495 | 0.270 |
Why?
|
Pregnancy Trimester, Third | 1 | 2008 | 582 | 0.260 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2016 | 10344 | 0.260 |
Why?
|
Recurrence | 8 | 2020 | 8482 | 0.260 |
Why?
|
Pregnancy Trimester, Second | 1 | 2008 | 732 | 0.260 |
Why?
|
Body Mass Index | 3 | 2020 | 12914 | 0.260 |
Why?
|
Infant Welfare | 1 | 2005 | 80 | 0.260 |
Why?
|
Fertilization in Vitro | 1 | 2013 | 1292 | 0.250 |
Why?
|
Faculty | 1 | 2008 | 383 | 0.250 |
Why?
|
Referral and Consultation | 3 | 2014 | 3598 | 0.250 |
Why?
|
Advisory Committees | 3 | 2019 | 788 | 0.240 |
Why?
|
Terminology as Topic | 2 | 2009 | 1535 | 0.240 |
Why?
|
Disease Susceptibility | 1 | 2011 | 1791 | 0.240 |
Why?
|
Pandemics | 3 | 2023 | 8624 | 0.240 |
Why?
|
Sudden Infant Death | 1 | 2007 | 291 | 0.240 |
Why?
|
Affect | 4 | 2023 | 1480 | 0.230 |
Why?
|
Risk Factors | 17 | 2023 | 74359 | 0.230 |
Why?
|
Cognition | 4 | 2017 | 6957 | 0.230 |
Why?
|
Adolescent | 18 | 2022 | 87810 | 0.220 |
Why?
|
Postnatal Care | 1 | 2005 | 260 | 0.220 |
Why?
|
Leuprolide | 2 | 2016 | 315 | 0.220 |
Why?
|
Hypertension, Pulmonary | 1 | 2014 | 1570 | 0.220 |
Why?
|
Placebos | 5 | 2014 | 1668 | 0.220 |
Why?
|
Vitamin D | 2 | 2022 | 3291 | 0.210 |
Why?
|
Mental Health Services | 3 | 2024 | 1717 | 0.210 |
Why?
|
Leadership | 1 | 2012 | 1371 | 0.210 |
Why?
|
United States | 18 | 2021 | 72461 | 0.210 |
Why?
|
Premenstrual Syndrome | 2 | 2017 | 107 | 0.210 |
Why?
|
Testosterone | 2 | 2004 | 2470 | 0.210 |
Why?
|
Obstetrics | 1 | 2009 | 667 | 0.200 |
Why?
|
Folic Acid | 4 | 2016 | 1309 | 0.200 |
Why?
|
Parturition | 2 | 2023 | 446 | 0.200 |
Why?
|
Biological Psychiatry | 1 | 2022 | 26 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3085 | 0.200 |
Why?
|
Career Choice | 1 | 2008 | 754 | 0.200 |
Why?
|
Nasal Sprays | 1 | 2022 | 20 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3205 | 0.200 |
Why?
|
Infant, Newborn | 10 | 2023 | 26181 | 0.200 |
Why?
|
Buspirone | 1 | 2022 | 81 | 0.200 |
Why?
|
Conflict of Interest | 1 | 2007 | 549 | 0.200 |
Why?
|
Sexual Behavior | 2 | 2009 | 2086 | 0.190 |
Why?
|
Clozapine | 3 | 2003 | 506 | 0.190 |
Why?
|
Cyclohexanecarboxylic Acids | 2 | 2003 | 140 | 0.190 |
Why?
|
Comorbidity | 7 | 2017 | 10551 | 0.190 |
Why?
|
Disease Progression | 1 | 2018 | 13502 | 0.190 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 2002 | 165 | 0.190 |
Why?
|
Estradiol | 2 | 2020 | 1932 | 0.190 |
Why?
|
Serotonin 5-HT2 Receptor Antagonists | 1 | 2020 | 23 | 0.190 |
Why?
|
Tachyphylaxis | 2 | 2018 | 54 | 0.180 |
Why?
|
Luteal Phase | 1 | 2021 | 138 | 0.180 |
Why?
|
Amines | 2 | 2003 | 281 | 0.180 |
Why?
|
Male | 34 | 2022 | 359744 | 0.180 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 4 | 2014 | 1988 | 0.180 |
Why?
|
Drug Industry | 1 | 2007 | 789 | 0.180 |
Why?
|
Obesity | 2 | 2020 | 12922 | 0.180 |
Why?
|
Child Health Services | 1 | 2005 | 644 | 0.170 |
Why?
|
Sex Factors | 7 | 2013 | 10547 | 0.170 |
Why?
|
Herbal Medicine | 2 | 2010 | 36 | 0.170 |
Why?
|
Longevity | 2 | 2023 | 1050 | 0.160 |
Why?
|
Awareness | 1 | 2023 | 646 | 0.160 |
Why?
|
Menarche | 1 | 2002 | 529 | 0.160 |
Why?
|
Practice Guidelines as Topic | 4 | 2024 | 7475 | 0.160 |
Why?
|
Exercise | 3 | 2014 | 5787 | 0.160 |
Why?
|
Receptors, Opioid, kappa | 1 | 2020 | 138 | 0.160 |
Why?
|
Adaptation, Psychological | 2 | 2023 | 2628 | 0.160 |
Why?
|
Suicidal Ideation | 3 | 2023 | 1425 | 0.150 |
Why?
|
Anniversaries and Special Events | 1 | 2019 | 94 | 0.150 |
Why?
|
Pyrrolidines | 1 | 2020 | 340 | 0.150 |
Why?
|
Cooperative Behavior | 1 | 2005 | 1500 | 0.150 |
Why?
|
Drug Administration Schedule | 3 | 2018 | 4899 | 0.150 |
Why?
|
Syndrome | 1 | 2024 | 3280 | 0.150 |
Why?
|
Evidence-Based Medicine | 2 | 2009 | 3696 | 0.150 |
Why?
|
Feeding Behavior | 1 | 2010 | 3185 | 0.150 |
Why?
|
Magnetic Field Therapy | 1 | 2017 | 27 | 0.150 |
Why?
|
Eligibility Determination | 2 | 2019 | 421 | 0.140 |
Why?
|
Professional Role | 1 | 2020 | 310 | 0.140 |
Why?
|
Schizophrenia, Paranoid | 1 | 2017 | 102 | 0.140 |
Why?
|
Ethinyl Estradiol | 1 | 2017 | 114 | 0.140 |
Why?
|
Delayed-Action Preparations | 2 | 2016 | 961 | 0.140 |
Why?
|
Infant | 8 | 2023 | 36060 | 0.140 |
Why?
|
Triazines | 3 | 2016 | 310 | 0.140 |
Why?
|
Qualitative Research | 2 | 2024 | 2963 | 0.140 |
Why?
|
Suicide | 2 | 2023 | 1599 | 0.140 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2020 | 357 | 0.140 |
Why?
|
Case-Control Studies | 4 | 2021 | 22053 | 0.130 |
Why?
|
Androgens | 1 | 2004 | 1291 | 0.130 |
Why?
|
Texas | 2 | 2014 | 401 | 0.130 |
Why?
|
Androstenes | 1 | 2017 | 182 | 0.130 |
Why?
|
gamma-Aminobutyric Acid | 2 | 2003 | 1132 | 0.130 |
Why?
|
Pilot Projects | 4 | 2014 | 8555 | 0.130 |
Why?
|
Infusions, Intravenous | 4 | 2022 | 2234 | 0.130 |
Why?
|
Progesterone | 1 | 2020 | 742 | 0.130 |
Why?
|
Severity of Illness Index | 5 | 2014 | 15840 | 0.130 |
Why?
|
Physician-Patient Relations | 1 | 2009 | 3242 | 0.130 |
Why?
|
Lactation | 2 | 2009 | 397 | 0.130 |
Why?
|
Midazolam | 3 | 2022 | 267 | 0.120 |
Why?
|
Arizona | 2 | 2005 | 107 | 0.120 |
Why?
|
Narcotic Antagonists | 1 | 2020 | 583 | 0.120 |
Why?
|
Exercise Therapy | 4 | 2013 | 919 | 0.120 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2016 | 276 | 0.120 |
Why?
|
Parents | 1 | 2009 | 3549 | 0.120 |
Why?
|
Biomarkers, Pharmacological | 1 | 2015 | 162 | 0.120 |
Why?
|
Attitude of Health Personnel | 1 | 2009 | 3865 | 0.120 |
Why?
|
Weight Gain | 2 | 2020 | 2347 | 0.120 |
Why?
|
Milk, Human | 2 | 2009 | 483 | 0.120 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2003 | 1529 | 0.120 |
Why?
|
Personality Disorders | 2 | 2009 | 721 | 0.120 |
Why?
|
Patient Care | 1 | 2020 | 624 | 0.120 |
Why?
|
Benzamides | 1 | 2020 | 1369 | 0.110 |
Why?
|
Psychological Techniques | 1 | 2013 | 47 | 0.110 |
Why?
|
Psychopharmacology | 1 | 2015 | 148 | 0.110 |
Why?
|
Feasibility Studies | 2 | 2014 | 5201 | 0.110 |
Why?
|
Fertilization | 1 | 2014 | 197 | 0.110 |
Why?
|
Massage | 1 | 2013 | 86 | 0.110 |
Why?
|
Life Style | 2 | 2008 | 3896 | 0.110 |
Why?
|
Nutritional Physiological Phenomena | 1 | 2015 | 363 | 0.110 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2009 | 791 | 0.110 |
Why?
|
Neuropsychological Tests | 2 | 2017 | 7021 | 0.110 |
Why?
|
Thinking | 1 | 2016 | 319 | 0.110 |
Why?
|
Risk Assessment | 5 | 2018 | 24123 | 0.100 |
Why?
|
Schizophrenia | 2 | 2002 | 6915 | 0.100 |
Why?
|
Contraceptives, Oral | 2 | 2007 | 554 | 0.100 |
Why?
|
Interprofessional Relations | 2 | 2009 | 989 | 0.100 |
Why?
|
Affective Disorders, Psychotic | 1 | 2013 | 186 | 0.100 |
Why?
|
Persistent Fetal Circulation Syndrome | 1 | 2012 | 80 | 0.100 |
Why?
|
Bupropion | 1 | 2014 | 304 | 0.100 |
Why?
|
Gravidity | 2 | 2002 | 50 | 0.100 |
Why?
|
Drug Storage | 1 | 2011 | 52 | 0.100 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2016 | 861 | 0.100 |
Why?
|
Child Care | 1 | 2012 | 121 | 0.100 |
Why?
|
Drug Substitution | 1 | 2014 | 296 | 0.100 |
Why?
|
Longitudinal Studies | 3 | 2020 | 14495 | 0.090 |
Why?
|
Synaptic Membranes | 1 | 2011 | 89 | 0.090 |
Why?
|
Patient Compliance | 2 | 2013 | 2688 | 0.090 |
Why?
|
Hypolipidemic Agents | 1 | 2015 | 626 | 0.090 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2016 | 1153 | 0.090 |
Why?
|
Certification | 1 | 2014 | 421 | 0.090 |
Why?
|
Half-Life | 1 | 2011 | 652 | 0.090 |
Why?
|
Remission Induction | 1 | 2016 | 2392 | 0.090 |
Why?
|
Withholding Treatment | 1 | 2014 | 613 | 0.090 |
Why?
|
Physicians | 1 | 2008 | 4591 | 0.080 |
Why?
|
Plant Preparations | 1 | 2010 | 94 | 0.080 |
Why?
|
Drug Combinations | 1 | 2015 | 2025 | 0.080 |
Why?
|
1-Naphthylamine | 1 | 2008 | 49 | 0.080 |
Why?
|
Benzhydryl Compounds | 1 | 2016 | 941 | 0.080 |
Why?
|
Health Services Accessibility | 2 | 2024 | 5397 | 0.080 |
Why?
|
Maternal-Fetal Exchange | 1 | 2011 | 463 | 0.080 |
Why?
|
Overweight | 1 | 2020 | 2421 | 0.080 |
Why?
|
Nutritional Requirements | 1 | 2010 | 275 | 0.080 |
Why?
|
Parity | 2 | 2002 | 925 | 0.080 |
Why?
|
Journal Impact Factor | 1 | 2009 | 156 | 0.080 |
Why?
|
Patient Education as Topic | 1 | 2018 | 2315 | 0.080 |
Why?
|
Work Schedule Tolerance | 1 | 2012 | 551 | 0.080 |
Why?
|
Belgium | 1 | 2008 | 118 | 0.080 |
Why?
|
Time Factors | 3 | 2016 | 40165 | 0.070 |
Why?
|
Aged | 12 | 2020 | 169152 | 0.070 |
Why?
|
Cold Temperature | 1 | 2011 | 780 | 0.070 |
Why?
|
Methionine | 1 | 2010 | 569 | 0.070 |
Why?
|
Medical History Taking | 1 | 2011 | 773 | 0.070 |
Why?
|
Diabetes, Gestational | 1 | 2017 | 1242 | 0.070 |
Why?
|
Triglycerides | 1 | 2015 | 2476 | 0.070 |
Why?
|
Electroconvulsive Therapy | 2 | 2005 | 502 | 0.070 |
Why?
|
Nonprescription Drugs | 1 | 2008 | 118 | 0.070 |
Why?
|
Canada | 2 | 2023 | 2128 | 0.070 |
Why?
|
Meditation | 1 | 2010 | 251 | 0.070 |
Why?
|
Pregnancy, Unplanned | 1 | 2007 | 88 | 0.070 |
Why?
|
Organizational Policy | 1 | 2009 | 429 | 0.070 |
Why?
|
Sample Size | 1 | 2010 | 840 | 0.070 |
Why?
|
Personality Inventory | 1 | 2010 | 1018 | 0.070 |
Why?
|
Pharmaceutical Services | 1 | 2008 | 141 | 0.070 |
Why?
|
Activities of Daily Living | 1 | 2016 | 2417 | 0.070 |
Why?
|
Food Preferences | 1 | 2010 | 399 | 0.070 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 1 | 2008 | 324 | 0.070 |
Why?
|
Social Environment | 2 | 2008 | 1022 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3310 | 0.070 |
Why?
|
Birth Weight | 1 | 2014 | 2097 | 0.070 |
Why?
|
Cholesterol | 1 | 2015 | 2924 | 0.070 |
Why?
|
Fatty Acids, Omega-6 | 1 | 2007 | 227 | 0.070 |
Why?
|
Societies, Medical | 3 | 2019 | 3905 | 0.070 |
Why?
|
Research Design | 4 | 2013 | 6180 | 0.070 |
Why?
|
Program Evaluation | 1 | 2014 | 2493 | 0.060 |
Why?
|
Maternal Behavior | 1 | 2008 | 306 | 0.060 |
Why?
|
Catecholamines | 1 | 2006 | 385 | 0.060 |
Why?
|
Patient Dropouts | 1 | 2007 | 412 | 0.060 |
Why?
|
Self Report | 1 | 2017 | 3711 | 0.060 |
Why?
|
Tremor | 1 | 2006 | 187 | 0.060 |
Why?
|
Drug Utilization | 1 | 2011 | 1195 | 0.060 |
Why?
|
Sex Distribution | 2 | 2008 | 2295 | 0.060 |
Why?
|
Plant Extracts | 1 | 2008 | 496 | 0.060 |
Why?
|
Drug Therapy | 1 | 2008 | 504 | 0.060 |
Why?
|
Tryptophan | 1 | 2006 | 479 | 0.060 |
Why?
|
Health Services Needs and Demand | 1 | 2012 | 1399 | 0.060 |
Why?
|
Neurogenesis | 1 | 2011 | 856 | 0.060 |
Why?
|
5-Hydroxytryptophan | 1 | 2004 | 32 | 0.060 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2014 | 1200 | 0.060 |
Why?
|
Pregnanes | 1 | 2023 | 7 | 0.060 |
Why?
|
Brain | 1 | 2011 | 26951 | 0.060 |
Why?
|
Libido | 1 | 2004 | 119 | 0.060 |
Why?
|
Data Interpretation, Statistical | 1 | 2013 | 2696 | 0.060 |
Why?
|
Cross-Sectional Studies | 4 | 2024 | 25942 | 0.050 |
Why?
|
Epidemiologic Studies | 1 | 2006 | 670 | 0.050 |
Why?
|
Netherlands | 1 | 2008 | 2213 | 0.050 |
Why?
|
Pirenzepine | 1 | 2003 | 116 | 0.050 |
Why?
|
Treatment Refusal | 1 | 2006 | 430 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2022 | 39261 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 7806 | 0.050 |
Why?
|
Lithium Carbonate | 1 | 2003 | 179 | 0.050 |
Why?
|
Tissue Distribution | 1 | 2006 | 2262 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3018 | 0.050 |
Why?
|
Research Support as Topic | 1 | 2007 | 699 | 0.050 |
Why?
|
Child | 6 | 2023 | 79806 | 0.050 |
Why?
|
Climacteric | 1 | 2002 | 57 | 0.050 |
Why?
|
Choice Behavior | 1 | 2008 | 821 | 0.050 |
Why?
|
Amphetamine | 1 | 2023 | 224 | 0.050 |
Why?
|
Social Support | 1 | 2011 | 2145 | 0.050 |
Why?
|
Folic Acid Deficiency | 1 | 2002 | 117 | 0.050 |
Why?
|
Huntington Disease | 1 | 2008 | 1141 | 0.050 |
Why?
|
History, 21st Century | 1 | 2008 | 1575 | 0.050 |
Why?
|
Program Development | 1 | 2008 | 1297 | 0.050 |
Why?
|
Injections, Intramuscular | 1 | 2003 | 553 | 0.050 |
Why?
|
Fructose | 1 | 2003 | 287 | 0.050 |
Why?
|
Hypothyroidism | 1 | 2006 | 665 | 0.050 |
Why?
|
Causality | 1 | 2007 | 1242 | 0.050 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2005 | 377 | 0.050 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2009 | 4555 | 0.050 |
Why?
|
Acetates | 2 | 2003 | 321 | 0.050 |
Why?
|
Interpersonal Relations | 1 | 2008 | 1428 | 0.040 |
Why?
|
Self-Injurious Behavior | 1 | 2007 | 554 | 0.040 |
Why?
|
Neural Tube Defects | 1 | 2002 | 254 | 0.040 |
Why?
|
Prejudice | 1 | 2004 | 563 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2014 | 3976 | 0.040 |
Why?
|
History, 20th Century | 1 | 2008 | 2773 | 0.040 |
Why?
|
Yoga | 2 | 2014 | 281 | 0.040 |
Why?
|
Family Health | 1 | 2004 | 1257 | 0.040 |
Why?
|
Feedback | 1 | 2023 | 791 | 0.040 |
Why?
|
Vasomotor System | 1 | 2020 | 207 | 0.040 |
Why?
|
Ovulation | 1 | 2020 | 181 | 0.040 |
Why?
|
Calcium Channel Blockers | 2 | 2003 | 694 | 0.040 |
Why?
|
Drug Prescriptions | 1 | 2008 | 1673 | 0.040 |
Why?
|
Guidelines as Topic | 1 | 2004 | 1392 | 0.040 |
Why?
|
Body Weight | 1 | 2008 | 4611 | 0.040 |
Why?
|
Psychomotor Performance | 1 | 2006 | 1878 | 0.040 |
Why?
|
Zinc | 1 | 2022 | 689 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2021 | 1578 | 0.040 |
Why?
|
Obsessive-Compulsive Disorder | 1 | 2007 | 1489 | 0.040 |
Why?
|
Body Image | 1 | 2022 | 635 | 0.040 |
Why?
|
Diet | 1 | 2015 | 8010 | 0.030 |
Why?
|
Prevalence | 2 | 2005 | 15687 | 0.030 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2017 | 116 | 0.030 |
Why?
|
Waist Circumference | 1 | 2020 | 926 | 0.030 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2020 | 542 | 0.030 |
Why?
|
Hormone Replacement Therapy | 1 | 2002 | 755 | 0.030 |
Why?
|
Delphi Technique | 1 | 2020 | 829 | 0.030 |
Why?
|
Fertility Agents, Female | 1 | 2016 | 101 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2006 | 2255 | 0.030 |
Why?
|
Attitude to Health | 1 | 2005 | 2029 | 0.030 |
Why?
|
Prognosis | 2 | 2010 | 29658 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2008 | 3448 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2002 | 12965 | 0.030 |
Why?
|
Models, Psychological | 1 | 1999 | 827 | 0.030 |
Why?
|
Age of Onset | 1 | 2002 | 3301 | 0.030 |
Why?
|
Random Allocation | 1 | 2019 | 2394 | 0.030 |
Why?
|
Pregnancy Trimesters | 1 | 2015 | 197 | 0.030 |
Why?
|
Forecasting | 1 | 2023 | 2932 | 0.030 |
Why?
|
Genotype | 1 | 2008 | 12960 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2008 | 3986 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 1999 | 2061 | 0.030 |
Why?
|
Pyrazoles | 1 | 2023 | 1999 | 0.030 |
Why?
|
Caregivers | 1 | 2004 | 2224 | 0.030 |
Why?
|
Decision Making | 1 | 2005 | 3925 | 0.020 |
Why?
|
Acute Disease | 1 | 2002 | 7269 | 0.020 |
Why?
|
Inflammation | 1 | 2011 | 10756 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5877 | 0.020 |
Why?
|
Schizophrenic Psychology | 1 | 2017 | 1646 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 3113 | 0.020 |
Why?
|
Signal Transduction | 2 | 2011 | 23376 | 0.020 |
Why?
|
Animals | 2 | 2011 | 167963 | 0.020 |
Why?
|
Smoking | 1 | 2005 | 9073 | 0.020 |
Why?
|
Women's Health Services | 1 | 2008 | 89 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2015 | 2435 | 0.020 |
Why?
|
Glycosides | 1 | 2008 | 111 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2005 | 20080 | 0.020 |
Why?
|
Quality of Life | 1 | 2008 | 13308 | 0.020 |
Why?
|
Drug Resistance | 1 | 2011 | 1617 | 0.020 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2014 | 1079 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2009 | 58995 | 0.010 |
Why?
|
Indans | 1 | 2003 | 91 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2008 | 2932 | 0.010 |
Why?
|
Age Distribution | 1 | 2008 | 2893 | 0.010 |
Why?
|
Child, Preschool | 1 | 2024 | 42063 | 0.010 |
Why?
|
Primary Prevention | 1 | 2008 | 1207 | 0.010 |
Why?
|
Synaptic Transmission | 1 | 2006 | 1171 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 5508 | 0.010 |
Why?
|
Cohort Studies | 1 | 2002 | 41335 | 0.010 |
Why?
|
Antihypertensive Agents | 1 | 2008 | 2061 | 0.010 |
Why?
|
Sleep | 1 | 2014 | 4751 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2006 | 6238 | 0.010 |
Why?
|
Odds Ratio | 1 | 2008 | 9716 | 0.010 |
Why?
|
Thiazoles | 1 | 2003 | 1511 | 0.010 |
Why?
|
Anticoagulants | 1 | 2008 | 4897 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2008 | 7408 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2006 | 80372 | 0.000 |
Why?
|